Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
25 results
  • Amphotericin B: A drug of choice for Visceral Leishmaniasis. [Review]
    Acta Trop. 2022 Nov; 235:106661.Kumari S, Kumar V, … Kumar A
  • Visceral leishmaniasis or Kala-azar is a vector-borne disease caused by an intracellular parasite of the genus leishmania. In India, Amphotericin B (AmB) is a first-line medication for treating leishmaniasis. After a large-scale resistance to pentavalent antimony therapy developed in Bihar state, it was rediscovered as an effective treatment for Leishmania donovani infection. AmB which binds to t…
  • Drugs and Lactation Database (LactMed): Amphotericin B [BOOK]
    Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
  • Although no information exists on the milk excretion of amphotericin B, it is highly protein bound, has a large molecular weight, is virtually unabsorbed orally and has been use directly in the mouths of infants;[1] therefore, most reviewers consider it acceptable to use in nursing mothers.[2,3]
  • Amphotericin B formulations and drug targeting. [Review]
    J Pharm Sci. 2008 Jul; 97(7):2405-25.Torrado JJ, Espada R, … Torrado-Santiago S
  • Amphotericin B is a low-soluble polyene antibiotic which is able to self-aggregate. The aggregation state can modify its activity and pharmacokinetical characteristics. In spite of its high toxicity it is still widely employed for the treatment of systemic fungal infections and parasitic disease and different formulations are marketed. Some of these formulations, such as liposomal formulations, c…
  • Chemotherapy of leishmaniasis: recent advances in the treatment of visceral disease. [Journal Article]
    Curr Opin Infect Dis. 1998 Dec; 11(6):707-10.Berman J
  • New lipid formulations of amphotericin B--AmBisome, Amphotec, and Abelcet--have dramatically decreased the toxicity associated with amphotericin B and have made this group of agents the treatment of choice for visceral leishmaniasis. An agent of a completely different chemical class, the aminoglycoside aminosidine, was 97% curative in India. This agent too may be used for visceral leishmaniasis.
  • Two cases of cutaneous cryptococcosis. [Case Reports]
    Mycoses. 2005 Jul; 48(4):238-41.Xiujiao X, Ai'e X
  • We report two cases of cutaneous cryptococcosis in male patients without underlying disease. Case 1 had a granulomatous mass on his right neck, gradually enlarging for 3 months. After the mass was debrided surgically in a hospital, the incision wound gradually developed into a severe ulceration. Mycological examination revealed Cryptococcus neoformans infection. It was significant that histopatho…
  • [Visceral leishmaniasis: new drugs]. [Review]
    Arch Pediatr. 2003 Dec; 10 Suppl 5:550s-556s.Minodier P, Robert S, … Garnier JM
  • The standard treatment of visceral leishmaniasis is pentavalent antimony (meglumine antimoniate or sodium stibogluconate), but toxicity is frequent with this drug. Moreover, antimony unresponsiveness is increasing, both in immunocompetent and in immunosuppressed patients. Amphotericin B is a polyene macrolide antibiotic that binds to sterols in cell membranes. It is the most active antileishmania…
  • Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. [Review]
    Fundam Clin Pharmacol. 2003 Apr; 17(2):183-8.Minodier P, Retornaz K, … Garnier JM
  • The leishmaniases are protozoan diseases caused by Leishmania parasites. The first-line treatment of its visceral forms is pentavalent antimony (meglumine antimoniate or sodium stibogluconate), but toxicity is frequent with this drug. Moreover antimony unresponsiveness is increasing in Leishmania infantum and L. donovani foci, both in immunocompetent and in immunosuppressed patients. Amphotericin…
  • [Nephrotoxicity of amphotericin B]. [Review]
    Nephrologie. 2002; 23(3):119-22.Deray G, Mercadal L, Bagnis C
  • Amphotericin B is widely used for severe life threatening fungal infections. Its use is limited by a dose-dependent nephrotoxicity manifested by a reduction in glomerular filtration rate and tubular dysfunction. An elevated creatinine associated with amphotericin B is not only a marker for renal dysfunction but is also linked to a substantial risk for the use of hemodialysis and a higher mortalit…
  • Overview of the lipid formulations of amphotericin B. [Review]
    J Antimicrob Chemother. 2002 Feb; 49 Suppl 1:31-6.Dupont B
  • Invasive fungal infections have been increasingly recognized as a major cause of morbidity and mortality in the immunocompromised host. Amphotericin B has a broad spectrum and has remained the drug of choice for life-threatening invasive fungal infections. However, adverse events, particularly renal insufficiency, are limiting factors in achieving an effective dose: the prescription of amphoteric…
  • Lipid-based antifungal agents: current status. [Review]
    Curr Pharm Des. 2001 Mar; 7(5):393-415.Arikan S, Rex JH
  • Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations of ex…
  • A comparative review of conventional and lipid formulations of amphotericin B. [Practice Guideline]
    J Clin Pharm Ther. 1999 Aug; 24(4):249-57.Robinson RF, Nahata MC
  • Over the past 15 years, factors suh as corticosteroid treatment, cytotoxic chemotherapy, excessive use of broad spectrum antibiotics and HIV have led to an increased risk of serious fungal infections in both adults and pediatric patients. This increase in invasive fungal infections poses increasing difficulty in their treatment. Three new lipid formulations of amphotericin B are now available in …
  • Lipid formulations of amphotericin B: clinical efficacy and toxicities. [Review]
    Clin Infect Dis. 1998 Sep; 27(3):603-18.Wong-Beringer A, Jacobs RA, Guglielmo BJ
  • Commercially available lipid formulations of amphotericin B (Abelcet, Amphotec, and AmBisome) represent a significant advance in drug delivery technology. Differences in biochemical, pharmacokinetic, and pharmacodynamic properties among the lipid products have been shown in in vitro and in vivo models. Clinical experience with these products has been primarily in patients either refractory to or …
  • Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. [Journal Article]
    Clin Infect Dis. 1998 Feb; 26(2):461-7.Noskin GA, Pietrelli L, … Liang LJ
  • The efficacy and safety of amphotericin B colloidal dispersion (ABCD; Amphotec, Sequus Pharmaceuticals, Menlo Park, CA), a lipid complex of amphotericin B, were evaluated in immunocompromised patients with candidemia. These patients were recruited from five open-label clinical trials of ABCD therapy for fungal infections subsequent to bone marrow transplantation, hematologic malignancies, solid t…
New Search